Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Alternative compounded versions of Novo Nordisk’s blockbuster weight-loss and diabetes drugs have hurt its sales, ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...

Lars Fruergaard Jørgensen, the boss of Danish pharmaceutical giant Novo Nordisk, explained what impact the drugs can have on users weight in the long run ...

Despite Ozempic being the most recognisable brand name, as far as the people prescribing it are concerned weight loss is ...

A grandma of 11 and a New Jersey man have joined the growing chorus of users of the wildly popular weight-loss drugs Ozempic ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention. Helen Coffey speaks to the dentists warning that jabs could have a worrying im ...